tradingkey.logo

AtriCure Inc

ATRC

35.130USD

+0.120+0.34%
Market hours ETQuotes delayed by 15 min
1.75BMarket Cap
LossP/E TTM

AtriCure Inc

35.130

+0.120+0.34%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
44 / 207
Overall Ranking
146 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 9 analysts
Buy
Current Rating
51.000
Target Price
+41.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.84% year-on-year.
Fairly Valued
The company’s latest PE is -45.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.65M shares, decreasing 9.96% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.90M shares of this stock.

Financial Health

Currency: USD Updated2025-09-17

The company's current financial score is 8.01, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 136.14M, representing a year-over-year increase of 17.09%, while its net profit experienced a year-over-year increase of 22.70%.

Score

Industry at a Glance

Previous score
7.54
Change
0.47

Financials

9.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

3.50

Operational Efficiency

10.00

Growth Potential

9.70

Shareholder Returns

7.57

Company Valuation

Currency: USD Updated2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -45.51, which is -20.10% below the recent high of -36.36 and -10.57% above the recent low of -50.32.

Score

Industry at a Glance

Previous score
2.00
Change
-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 44/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-17

The company’s current earnings forecast score is 8.67, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for AtriCure Inc is 51.50, with a high of 60.00 and a low of 40.00.

Score

Industry at a Glance

Previous score
8.67
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts
Buy
Current Rating
51.000
Target Price
+41.82%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
AtriCure Inc
ATRC
9
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-17

The company’s current price momentum score is 6.37, which is lower than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 37.49 and the support level at 33.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.80
Change
-0.43

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.490
Neutral
RSI(14)
47.466
Neutral
STOCH(KDJ)(9,3,3)
27.776
Neutral
ATR(14)
1.563
High Vlolatility
CCI(14)
-84.830
Neutral
Williams %R
79.301
Sell
TRIX(12,20)
0.038
Sell
StochRSI(14)
14.079
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
35.646
Sell
MA10
35.653
Sell
MA20
36.214
Sell
MA50
34.457
Buy
MA100
33.464
Buy
MA200
34.383
Buy

Institutional Confidence

Currency: USD Updated2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 105.93%, representing a quarter-over-quarter decrease of 1.87%. The largest institutional shareholder is The Vanguard, holding a total of 4.90M shares, representing 9.85% of shares outstanding, with 3.44% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
4.70M
+1.32%
AllianceBernstein L.P.
3.68M
-4.14%
BlackRock Institutional Trust Company, N.A.
3.57M
-2.52%
Hood River Capital Management LLC
3.00M
+2.58%
Macquarie Investment Management
2.44M
+2.59%
Champlain Investment Partners, LLC
2.14M
-15.45%
State Street Global Advisors (US)
1.28M
-5.09%
Neuberger Berman, LLC
1.19M
+26.29%
Geode Capital Management, L.L.C.
1.17M
+1.40%
1
2

Risk Assessment

Currency: USD Updated2025-09-17

The company’s current risk assessment score is 5.13, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.13
Change
0
Beta vs S&P 500 index
1.61
VaR
+4.55%
240-Day Maximum Drawdown
+31.44%
240-Day Volatility
+55.02%
Return
Best Daily Return
60 days
+10.72%
120 days
+10.72%
5 years
+18.35%
Worst Daily Return
60 days
-6.63%
120 days
-13.68%
5 years
-13.68%
Sharpe Ratio
60 days
+1.17
120 days
+0.26
5 years
+0.13
Risk Assessment
Maximum Drawdown
240 days
+31.44%
3 years
+65.60%
5 years
+77.21%
Return-to-Drawdown Ratio
240 days
+0.82
3 years
-0.09
5 years
-0.06
Skewness
240 days
+0.68
3 years
+0.43
5 years
+0.26
Volatility
Realised Volatility
240 days
+55.02%
5 years
+52.24%
Standardised True Range
240 days
+4.24%
5 years
+5.71%
Downside Risk-Adjusted Return
120 days
+38.25%
240 days
+38.25%
Maximum Daily Upside Volatility
60 days
+45.90%
Maximum Daily Downside Volatility
60 days
+34.34%
Liquidity
Average Turnover Rate
60 days
+1.03%
120 days
+1.15%
5 years
--
Turnover Deviation
20 days
-25.61%
60 days
-19.61%
120 days
-10.05%

Peer Comparison

Healthcare Equipment & Supplies
AtriCure Inc
AtriCure Inc
ATRC
6.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI